Acute myocardial infarction (AMI) is a common cardiovascular condition that progressively results in heart failure. In the present study, we have designed to load transforming growth factor beta 3 (TGF-β3) and cardio potential exosomes into the blended polycaprolactone/type I collagen (PCL/COL-1) nanofibrous patch (Exo@TGF-β3@NFs) and examined its feasibility for cardiac repair. The bioactivity of the developed NFs towards the migration and proliferation of human umbilical vein endothelial cells was determined using in vitro cell compatibility assays. Additionally, Exo@TGF-β3/NFs showed up-regulation of genes involved in angiogenesis and mesenchymal differentiations in vitro. The in vivo experiments performed 4 weeks after transplantation showed that the Exo@TGF-β3@NFs had a higher LV ejection fraction and fraction shortening functions. Subsequently, it has been determined that Exo@TGF-β3@NFs significantly reduced AMI size and fibrosis and increased scar thickness. The developed NFs approach will become a useful therapeutic approach for the treatment of AMI.

急性心肌梗死（AMI）是一种常见的心血管疾病，会逐渐导致心力衰竭。在本研究中，我们设计将转化生长因子β3 （TGF-β3）和心脏潜能外泌体加载到混合聚己内酯/I型胶原（PCL/COL-1）纳米纤维贴片（Exo@TGF-β3@NFs）中并检查了其用于心脏修复的可行性。使用体外细胞相容性测定确定了所开发的 NF 对人脐静脉内皮细胞迁移和增殖的生物活性。此外，Exo@TGF-β3/NFs在体外显示出参与血管生成和间质分化的基因上调。移植后4周进行的体内实验表明，Exo@TGF-β3@NFs具有更高的左室射血分数和缩短分数功能。随后，已确定 Exo@TGF-β3@NFs 显着减少 AMI 大小和纤维化，并增加疤痕厚度。所开发的 NFs 方法将成为治疗 AMI 的有用治疗方法。